Spyre Therapeutics Prices Upsized $403 Mln Public Offering Of 6.50 Mln Shares At $62.00/shr

Spyre Therapeutics priced a 6.50 million-share underwritten offering at $62.00 per share, expected to raise about $403 million in gross proceeds. The deal is a financing event for the clinical-stage biotech rather than an operating update, so the near-term impact is mainly on dilution and balance sheet strength. The announcement is likely company-specific and modestly relevant to trading in SYRE.

Analysis

Spyre Therapeutics priced a 6.50 million-share underwritten offering at $62.00 per share, expected to raise about $403 million in gross proceeds. The deal is a financing event for the clinical-stage biotech rather than an operating update, so the near-term impact is mainly on dilution and balance sheet strength. The announcement is likely company-specific and modestly relevant to trading in SYRE.